US ERA ARCHIVE DOCUMENT

Shaughnessy No.: 122804 Date Out of EAB: ADR | 6 1087 Environmental Fate Review Section #1 Hazard Evaluation Division (TS-769C) Action Code: 714 EAB #(s): 70045 Total Reviewing Time: 0.75 day

Reg./File # : 50658-EUP-1 Chemical Name: Abamectin Type Product : Insecticide Product Name : Avid Company Name : Merck : EUP for use on Citrus. Purpose Date Received: 10/28/86 Date Completed: Monitoring study requested: Monitoring study voluntarily: Deferrals to: Ecological Effects Branch Residue Chemistry Branch Toxicology Branch

To: George LaRocca

Product Manager 15

Registration Division (TS-767)

From: Akiva Abramovitch, Chief (Acting)

Exposure Assessment Branch

Attached, please find the EAB review of ...

1.a CHEMICAL:

Avermectin $B_{1}a$ Abamectin.

See chemical structure in earlier EAB review of 9/05/85 and previous reviews.

The active ingredient is composed of not less than 80% avermectin $B_{1}a$ and not more than 20% avermectin $B_{1}b$.

1.b Physical Properties:

See earlier reports.

2. TEST MATERIAL: Not Applicable

3. STUDY/ACTION TYPE:

An EUP Request for use on Citrus.

4. STUDY IDENTIFICATION: Acc # 265590, 265593 to 265597.

5. REVIEWED BY:

Akiva D. Abramovitch, Ph.D. Chemist Environmental Chemistry Review Section 1/EAB/HED/OPP

6. APPROVED BY:

Akiva D. Abramovitch, Acting Chief Environmental Chemistry Review Section 1/EAB/HED/OPP

7. CONCLUSIONS:

EAB found all the environmental fate data adequate for the purpose of an EUP on citrus in the EAB review of May 23, 1985. EAB recommended in the review of Sept. 10, 1985 to reduce the acreage for the EUP on citrus from the proposed 4000 acres. The present request is for 3200 acres is reasonable.

A summary of the environmental fate data for the EUP is shown in the EAB review of July 11, 1984 (see attachment)

8. RECOMMENDATIONS:

EAB concurs with the proposed EUP on Citrus (see attachment for label acreage and quantities).

A note to the PM.

The present submission contain studies on foliar dislogeable residues and exposure to workers who apply abamectin and quantitative risk assessment that should be redirected to EAB later on for the purpose of registration.

Heira Lhamon Date: ADD 1 A

- 9. BACKGROUND:
 - A. Introduction: See EAB reviews of May 23 and Sept. 5, 1985.
 - B. <u>Directions for Use:</u> Please see attached copy of the proposed label.
- 10. DISCUSSION OF INDIVIDUAL TESTS OR STUDIES: N/A
- 11. <u>COMPLETION OF ONE LINER:</u>
 Not completed.
- 12. <u>CBI APPENDIX</u>:
 None